This research study seeks depressed participants to test the effects of the combination of repetitive transcranial magnetic stimulation (TMS) and psychotherapy on brain function.
This study is enrolling eligible adults ages 18-65 with major depressive disorder, who are free of other serious medical conditions. If you are currently taking anti-depressants, you may still be eligible.
Depression, TMS, Psychotherapy and Brain Function Join a Research Study: Enrolling nationally from around the country To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010]. This research study seeks depressed participants to test the effects of the combination of repetitive transcranial magnetic stimulation (TMS) and psychotherapy on brain function. This study is enrolling eligible adults…
Read more
Major Depression and AV101 Join a Research Study: Enrolling nationally from around the country To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010]. The primary purpose of this research study is to evaluate the safety and effectiveness of the oral drug AV-101 (an antagonist of the glycine receptor) versus placebo. The study aims to determine…
Read more
A Shorter—but Effective—Treatment for PTSD Study finds written exposure therapy may be as effective as a lengthier first-line intervention Research supported by the National Institute of Mental Health has shown that a shorter therapy (written exposure therapy) may be just as effective as lengthier first-line treatments for PTSD. Learn more >>
Jonathon C. Arnold, Ph.D. University of Sydney, Australia 2009 Young Investigator Grant New research in mice reveals how THC, the main psychoactive compound in cannabis, can reduce the effectiveness of risperidone, an antipsychotic drug used widely to treat people with schizophrenia. Earlier studies have suggested that cannabis use can reduce the effectiveness of antipsychotic treatments and…
Read more
Depression, Repeated Doses of Ketamine, and Neuroimaging Join a Research Study: Enrolling nationally from around the country To find out if you qualify, email NIMH or call 1-877-646-3644 (1-877-MIND-NIH) [TTY: 1-866-411-1010]. The purpose of this study is to evaluate the rapid and sustained antidepressant effects of repeat doses of ketamine in the brain. We want to learn how ketamine affects…
Read more
Join a Research Study: Enrolling nationally from around the country. The primary purpose of this research study is to evaluate the safety and effectiveness of the oral drug AV-101 versus placebo. The study aims to determine if this experimental drug has antidepressant effects and fewer side effects than other novel treatments for depression. First steps to participate include calling NIMH, learning specifics about the study, asking about your eligibility, and consenting to participate.
The primary purpose of this research study is to evaluate the safety and effectiveness of the oral drug AV-101 (an antagonist of the glycine receptor) versus placebo. The study aims to determine if this experimental drug has antidepressant effects and fewer side effects than other novel treatments for depression.
Peak Behavioral Health Is Open
NAMI’s Statement on Recent Racist Incidents
June 2020 Newsletter
